4flp › Citations

Small-molecule inhibition of BRDT for male contraception.

Matzuk MM, McKeown MR, Filippakopoulos P, Li Q, Ma L, Agno JE, Lemieux ME, Picaud S, Yu RN, Qi J, Knapp S, Bradner JE
Cell 150 673-84 (2012)
Cited: 235 times
EuropePMC logo PMID: 22901802

Abstract

A pharmacologic approach to male contraception remains a longstanding challenge in medicine. Toward this objective, we explored the spermatogenic effects of a selective small-molecule inhibitor (JQ1) of the bromodomain and extraterminal (BET) subfamily of epigenetic reader proteins. Here, we report potent inhibition of the testis-specific member BRDT, which is essential for chromatin remodeling during spermatogenesis. Biochemical and crystallographic studies confirm that occupancy of the BRDT acetyl-lysine binding pocket by JQ1 prevents recognition of acetylated histone H4. Treatment of mice with JQ1 reduced seminiferous tubule area, testis size, and spermatozoa number and motility without affecting hormone levels. Although JQ1-treated males mate normally, inhibitory effects of JQ1 evident at the spermatocyte and round spermatid stages cause a complete and reversible contraceptive effect. These data establish a new contraceptive that can cross the blood:testis boundary and inhibit bromodomain activity during spermatogenesis, providing a lead compound targeting the male germ cell for contraception.

Articles - 4flp mentioned but not cited (10)

  1. Small-molecule inhibition of BRDT for male contraception. Matzuk MM, McKeown MR, Filippakopoulos P, Li Q, Ma L, Agno JE, Lemieux ME, Picaud S, Yu RN, Qi J, Knapp S, Bradner JE. Cell 150 673-684 (2012)
  2. Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. Martin MP, Olesen SH, Georg GI, Schönbrunn E. ACS Chem Biol 8 2360-2365 (2013)
  3. Protein-observed (19)F-NMR for fragment screening, affinity quantification and druggability assessment. Gee CT, Arntson KE, Urick AK, Mishra NK, Hawk LM, Wisniewski AJ, Pomerantz WC. Nat Protoc 11 1414-1427 (2016)
  4. BET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual Screen. Ayoub AM, Hawk LML, Herzig RJ, Jiang J, Wisniewski AJ, Gee CT, Zhao P, Zhu JY, Berndt N, Offei-Addo NK, Scott TG, Qi J, Bradner JE, Ward TR, Schönbrunn E, Georg GI, Pomerantz WCK. J Med Chem 60 4805-4817 (2017)
  5. HADDOCK(2P2I): a biophysical model for predicting the binding affinity of protein-protein interaction inhibitors. Kastritis PL, Rodrigues JP, Bonvin AM. J Chem Inf Model 54 826-836 (2014)
  6. Discovery and characterization of bromodomain 2-specific inhibitors of BRDT. Yu Z, Ku AF, Anglin JL, Sharma R, Ucisik MN, Faver JC, Li F, Nyshadham P, Simmons N, Sharma KL, Nagarajan S, Riehle K, Kaur G, Sankaran B, Storl-Desmond M, Palmer SS, Young DW, Kim C, Matzuk MM. Proc Natl Acad Sci U S A 118 e2021102118 (2021)
  7. The role of ZA channel water-mediated interactions in the design of bromodomain-selective BET inhibitors. Bharatham N, Slavish PJ, Shadrick WR, Young BM, Young BM, Shelat AA. J Mol Graph Model 81 197-210 (2018)
  8. Design, Synthesis, and Characterization of a Fluorescence Polarization Pan-BET Bromodomain Probe. Paulson CN, Guan X, Ayoub AM, Chan A, Karim RM, Pomerantz WCK, Schönbrunn E, Georg GI, Hawkinson JE. ACS Med Chem Lett 9 1223-1229 (2018)
  9. Identification of novel potent human testis-specific and bromodomain-containing protein (BRDT) inhibitors using crystal structure-based virtual screening. Gao N, Ren J, Hou L, Zhou Y, Xin L, Wang J, Yu H, Xie Y, Wang H. Int J Mol Med 38 39-44 (2016)
  10. Dihydropyridine Lactam Analogs Targeting BET Bromodomains. Jiang J, Sigua LH, Chan A, Kalra P, Pomerantz WCK, Schönbrunn E, Qi J, Georg GI. ChemMedChem 17 e202100407 (2022)


Reviews citing this publication (72)

  1. The growing landscape of lysine acetylation links metabolism and cell signalling. Choudhary C, Weinert BT, Nishida Y, Verdin E, Mann M. Nat Rev Mol Cell Biol 15 536-550 (2014)
  2. Targeting bromodomains: epigenetic readers of lysine acetylation. Filippakopoulos P, Knapp S. Nat Rev Drug Discov 13 337-356 (2014)
  3. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Shi J, Vakoc CR. Mol Cell 54 728-736 (2014)
  4. Functions of bromodomain-containing proteins and their roles in homeostasis and cancer. Fujisawa T, Filippakopoulos P. Nat Rev Mol Cell Biol 18 246-262 (2017)
  5. Protein lysine acetylation by p300/CBP. Dancy BM, Cole PA. Chem Rev 115 2419-2452 (2015)
  6. Readout of epigenetic modifications. Patel DJ, Wang Z. Annu Rev Biochem 82 81-118 (2013)
  7. Cause and consequence of cancer/testis antigen activation in cancer. Whitehurst AW. Annu Rev Pharmacol Toxicol 54 251-272 (2014)
  8. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins. Taniguchi Y. Int J Mol Sci 17 E1849 (2016)
  9. Clinical trials for BET inhibitors run ahead of the science. Andrieu G, Belkina AC, Denis GV. Drug Discov Today Technol 19 45-50 (2016)
  10. Lysine Acetylation Goes Global: From Epigenetics to Metabolism and Therapeutics. Ali I, Conrad RJ, Verdin E, Ott M. Chem Rev 118 1216-1252 (2018)
  11. Epigenetic regulation of the histone-to-protamine transition during spermiogenesis. Bao J, Bedford MT. Reproduction 151 R55-70 (2016)
  12. Targeting Cancer Cells with BET Bromodomain Inhibitors. Xu Y, Vakoc CR. Cold Spring Harb Perspect Med 7 a026674 (2017)
  13. The bromodomain: from epigenome reader to druggable target. Sanchez R, Meslamani J, Zhou MM. Biochim Biophys Acta 1839 676-685 (2014)
  14. Achieving clinical success with BET inhibitors as anti-cancer agents. Shorstova T, Foulkes WD, Witcher M. Br J Cancer 124 1478-1490 (2021)
  15. Epigenetic mechanisms of importance for drug treatment. Ivanov M, Barragan I, Ingelman-Sundberg M. Trends Pharmacol Sci 35 384-396 (2014)
  16. Molecular Pathways: Targeting MYC-induced metabolic reprogramming and oncogenic stress in cancer. Li B, Simon MC. Clin Cancer Res 19 5835-5841 (2013)
  17. Seeding collaborations to advance kinase science with the GSK Published Kinase Inhibitor Set (PKIS). Drewry DH, Willson TM, Zuercher WJ. Curr Top Med Chem 14 340-342 (2014)
  18. BET bromodomain inhibitors: a patent review. Garnier JM, Sharp PP, Burns CJ. Expert Opin Ther Pat 24 185-199 (2014)
  19. Bromodomains and their pharmacological inhibitors. Gallenkamp D, Gelato KA, Haendler B, Weinmann H. ChemMedChem 9 438-464 (2014)
  20. Melanoma epigenetics: novel mechanisms, markers, and medicines. Lee JJ, Murphy GF, Lian CG. Lab Invest 94 822-838 (2014)
  21. Bromodomain and extraterminal domain inhibitors (BETi) for cancer therapy: chemical modulation of chromatin structure. Qi J. Cold Spring Harb Perspect Biol 6 a018663 (2014)
  22. Unravelling the genomic targets of small molecules using high-throughput sequencing. Rodriguez R, Miller KM. Nat Rev Genet 15 783-796 (2014)
  23. Bromodomains as therapeutic targets in cancer. Barbieri I, Cannizzaro E, Dawson MA. Brief Funct Genomics 12 219-230 (2013)
  24. Sperm nuclear proteome and its epigenetic potential. Castillo J, Amaral A, Oliva R. Andrology 2 326-338 (2014)
  25. Inhibitors of bromodomain and extra-terminal proteins for treating multiple human diseases. Kulikowski E, Rakai BD, Wong NCW. Med Res Rev 41 223-245 (2021)
  26. Non-hormonal male contraception: A review and development of an Eppin based contraceptive. O'Rand MG, Silva EJ, Hamil KG. Pharmacol Ther 157 105-111 (2016)
  27. Mind the methyl: methyllysine binding proteins in epigenetic regulation. Wagner T, Robaa D, Sippl W, Jung M. ChemMedChem 9 466-483 (2014)
  28. Privileged diazepine compounds and their emergence as bromodomain inhibitors. Smith SG, Sanchez R, Zhou MM. Chem Biol 21 573-583 (2014)
  29. Supercharging BRD4 with NUT in carcinoma. Eagen KP, French CA. Oncogene 40 1396-1408 (2021)
  30. Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development. Tang P, Zhang J, Liu J, Chiang CM, Ouyang L. J Med Chem 64 2419-2435 (2021)
  31. Molecules targeting the androgen receptor (AR) signaling axis beyond the AR-Ligand binding domain. Elshan NGRD, Rettig MB, Jung ME. Med Res Rev 39 910-960 (2019)
  32. BET bromodomains as novel epigenetic targets for brain health and disease. Singh MB, Sartor GC. Neuropharmacology 181 108306 (2020)
  33. Bromodomain protein inhibition: a novel therapeutic strategy in rheumatic diseases. Klein K. RMD Open 4 e000744 (2018)
  34. Small-molecular modulators of cancer-associated epigenetic mechanisms. Itoh Y, Suzuki T, Miyata N. Mol Biosyst 9 873-896 (2013)
  35. Male contraception: another Holy Grail. Murdoch FE, Goldberg E. Bioorg Med Chem Lett 24 419-424 (2014)
  36. Targeting bromodomain and extraterminal proteins in breast cancer. Sahni JM, Keri RA. Pharmacol Res 129 156-176 (2018)
  37. BET inhibitors in cancer therapeutics: a patent review. Ghoshal A, Yugandhar D, Srivastava AK. Expert Opin Ther Pat 26 505-522 (2016)
  38. Epigenetic drugs and their molecular targets in testicular germ cell tumours. Jostes S, Nettersheim D, Schorle H. Nat Rev Urol 16 245-259 (2019)
  39. The control of male fertility by spermatid-specific factors: searching for contraceptive targets from spermatozoon's head to tail. Chen SR, Batool A, Wang YQ, Hao XX, Chang CS, Cheng CY, Liu YX. Cell Death Dis 7 e2472 (2016)
  40. Chemical Protein Degradation Approach and its Application to Epigenetic Targets. Itoh Y. Chem Rec 18 1681-1700 (2018)
  41. Male contraception. Amory JK. Fertil Steril 106 1303-1309 (2016)
  42. The application of proteomic approaches to the study of mammalian spermatogenesis and sperm function. Macleod G, Varmuza S. FEBS J 280 5635-5651 (2013)
  43. Innovation in academic chemical screening: filling the gaps in chemical biology. Hasson SA, Inglese J. Curr Opin Chem Biol 17 329-338 (2013)
  44. Manipulation of the host protein acetylation network by human immunodeficiency virus type 1. Jeng MY, Ali I, Ott M. Crit Rev Biochem Mol Biol 50 314-325 (2015)
  45. Selective targeting of epigenetic reader domains. Greschik H, Schüle R, Günther T. Expert Opin Drug Discov 12 449-463 (2017)
  46. Update on Novel Hormonal and Nonhormonal Male Contraceptive Development. Long JE, Lee MS, Blithe DL. J Clin Endocrinol Metab 106 e2381-e2392 (2021)
  47. Male contraception: history and development. Kogan P, Wald M. Urol Clin North Am 41 145-161 (2014)
  48. Male contraception. Chao J, Page ST, Anderson RA. Best Pract Res Clin Obstet Gynaecol 28 845-857 (2014)
  49. BET bromodomain proteins and epigenetic regulation of inflammation: implications for type 2 diabetes and breast cancer. Nicholas DA, Andrieu G, Strissel KJ, Nikolajczyk BS, Denis GV. Cell Mol Life Sci 74 231-243 (2017)
  50. On the role of germ cells in mammalian gonad development: quiet passengers or back-seat drivers? Rios-Rojas C, Bowles J, Koopman P. Reproduction 149 R181-91 (2015)
  51. Phenotypic screening and fragment-based approaches to the discovery of small-molecule bromodomain ligands. Jennings LE, Measures AR, Wilson BG, Conway SJ. Future Med Chem 6 179-204 (2014)
  52. Role of BET Inhibitors in Triple Negative Breast Cancers. Khandekar D, Tiriveedhi V. Cancers (Basel) 12 E784 (2020)
  53. Development of Novel Male Contraceptives. Amory JK. Clin Transl Sci 13 228-237 (2020)
  54. Pipeline for contraceptive development. Blithe DL. Fertil Steril 106 1295-1302 (2016)
  55. Toward Development of the Male Pill: A Decade of Potential Non-hormonal Contraceptive Targets. Kent K, Johnston M, Strump N, Garcia TX. Front Cell Dev Biol 8 61 (2020)
  56. BET proteins: Investigating BRDT as a potential target for male contraception. Wisniewski A, Georg GI. Bioorg Med Chem Lett 30 126958 (2020)
  57. Kinome-wide transcriptional profiling of uveal melanoma reveals new vulnerabilities to targeted therapeutics. Bailey FP, Clarke K, Kalirai H, Kenyani J, Shahidipour H, Falciani F, Coulson JM, Sacco JJ, Coupland SE, Eyers PA. Pigment Cell Melanoma Res 31 253-266 (2018)
  58. Male contraception: where are we going and where have we been? Reynolds-Wright JJ, Anderson R. BMJ Sex Reprod Health 45 236-242 (2019)
  59. Partners in crime: The role of tandem modules in gene transcription. Sharma R, Zhou MM. Protein Sci 24 1347-1359 (2015)
  60. The future of male contraception: a fertile ground. Khourdaji I, Zillioux J, Eisenfrats K, Foley D, Smith R. Transl Androl Urol 7 S220-S235 (2018)
  61. Bromodomain and extraterminal protein inhibitors in pediatrics: A review of the literature. Jiménez I, Baruchel A, Doz F, Schulte J. Pediatr Blood Cancer 64 (2017)
  62. Emerging approaches to male contraception. Thirumalai A, Amory JK. Fertil Steril 115 1369-1376 (2021)
  63. Out of sight, out of mind? Germ cells and the potential impacts of epigenomic drugs. Jarred EG, Bildsoe H, Western PS. F1000Res 7 F1000 Faculty Rev-1967 (2018)
  64. Super-Enhancers Dysregulations in Hematological Malignancies. Belloucif Y, Lobry C. Cells 11 196 (2022)
  65. [P-TEFb and Brd4: actors of the transcription pause release as therapeutical targets]. Furlan A, Agbazahou F, Henry M, Gonzalez-Pisfil M, Le Nézet C, Champelovier D, Fournier M, Vandenbunder B, Bidaux G, Héliot L. Med Sci (Paris) 34 685-692 (2018)
  66. Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy. Wang ZQ, Zhang ZC, Wu YY, Pi YN, Lou SH, Liu TB, Lou G, Yang C. Signal Transduct Target Ther 8 420 (2023)
  67. Recent progress and structural analyses of domain-selective BET inhibitors. Divakaran A, Harki DA, Pomerantz WCK. Med Res Rev 43 972-1018 (2023)
  68. BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications. To KKW, Xing E, Larue RC, Li PK. Molecules 28 3043 (2023)
  69. Emerging concepts in male contraception: a narrative review of novel, hormonal and non-hormonal options. Service CA, Puri D, Hsieh TC, Patel DP. Ther Adv Reprod Health 17 26334941221138323 (2023)
  70. Male contraception: narrative review of ongoing research. Louwagie EJ, Quinn GFL, Pond KL, Hansen KA. Basic Clin Androl 33 30 (2023)
  71. Non-Hormonal Contraception. Howard SA, Benhabbour SR. J Clin Med 12 4791 (2023)
  72. Various gene modification techniques to discover molecular targets for nonhormonal male contraceptives: A review. Yunaini L, Ari Pujianto D. Int J Reprod Biomed 21 17-32 (2023)

Articles citing this publication (153)

  1. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, Escara-Wilke J, Wilder-Romans K, Dhanireddy S, Engelke C, Iyer MK, Jing X, Wu YM, Cao X, Qin ZS, Wang S, Feng FY, Chinnaiyan AM. Nature 510 278-282 (2014)
  2. NF-κB directs dynamic super enhancer formation in inflammation and atherogenesis. Brown JD, Lin CY, Duan Q, Griffin G, Federation A, Paranal RM, Bair S, Newton G, Lichtman A, Kung A, Yang T, Wang H, Luscinskas FW, Croce K, Bradner JE, Plutzky J. Mol Cell 56 219-231 (2014)
  3. BET bromodomains mediate transcriptional pause release in heart failure. Anand P, Brown JD, Lin CY, Qi J, Zhang R, Artero PC, Alaiti MA, Bullard J, Alazem K, Margulies KB, Cappola TP, Lemieux M, Plutzky J, Bradner JE, Haldar SM. Cell 154 569-582 (2013)
  4. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Mazur PK, Herner A, Mello SS, Wirth M, Hausmann S, Sánchez-Rivera FJ, Lofgren SM, Kuschma T, Hahn SA, Vangala D, Trajkovic-Arsic M, Gupta A, Heid I, Noël PB, Braren R, Erkan M, Kleeff J, Sipos B, Sayles LC, Heikenwalder M, Heßmann E, Ellenrieder V, Esposito I, Jacks T, Bradner JE, Khatri P, Sweet-Cordero EA, Attardi LD, Schmid RM, Schneider G, Sage J, Siveke JT. Nat Med 21 1163-1171 (2015)
  5. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Picaud S, Wells C, Felletar I, Brotherton D, Martin S, Savitsky P, Diez-Dacal B, Philpott M, Bountra C, Lingard H, Fedorov O, Müller S, Brennan PE, Knapp S, Filippakopoulos P. Proc Natl Acad Sci U S A 110 19754-19759 (2013)
  6. Inhibition of BET bromodomain targets genetically diverse glioblastoma. Cheng Z, Gong Y, Ma Y, Lu K, Lu X, Pierce LA, Thompson RC, Muller S, Knapp S, Wang J. Clin Cancer Res 19 1748-1759 (2013)
  7. BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones. Kanno T, Kanno Y, LeRoy G, Campos E, Sun HW, Brooks SR, Vahedi G, Heightman TD, Garcia BA, Reinberg D, Siebenlist U, O'Shea JJ, Ozato K. Nat Struct Mol Biol 21 1047-1057 (2014)
  8. Oxidants, antioxidants and the current incurability of metastatic cancers. Watson J. Open Biol 3 120144 (2013)
  9. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression. Darcis G, Kula A, Bouchat S, Fujinaga K, Corazza F, Ait-Ammar A, Delacourt N, Melard A, Kabeya K, Vanhulle C, Van Driessche B, Gatot JS, Cherrier T, Pianowski LF, Gama L, Schwartz C, Vila J, Burny A, Clumeck N, Moutschen M, De Wit S, Peterlin BM, Rouzioux C, Rohr O, Van Lint C. PLoS Pathog 11 e1005063 (2015)
  10. Bromodomain-dependent stage-specific male genome programming by Brdt. Gaucher J, Boussouar F, Montellier E, Curtet S, Buchou T, Bertrand S, Hery P, Jounier S, Depaux A, Vitte AL, Guardiola P, Pernet K, Debernardi A, Lopez F, Holota H, Imbert J, Wolgemuth DJ, Gérard M, Rousseaux S, Khochbin S. EMBO J 31 3809-3820 (2012)
  11. Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. Gilan O, Rioja I, Knezevic K, Bell MJ, Yeung MM, Harker NR, Lam EYN, Chung CW, Bamborough P, Petretich M, Urh M, Atkinson SJ, Bassil AK, Roberts EJ, Vassiliadis D, Burr ML, Preston AGS, Wellaway C, Werner T, Gray JR, Michon AM, Gobbetti T, Kumar V, Soden PE, Haynes A, Vappiani J, Tough DF, Taylor S, Dawson SJ, Bantscheff M, Lindon M, Drewes G, Demont EH, Daniels DL, Grandi P, Prinjha RK, Dawson MA. Science 368 387-394 (2020)
  12. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Chen C, Liu Y, Lu C, Cross JR, Morris JP, Shroff AS, Ward PS, Bradner JE, Thompson C, Lowe SW. Genes Dev 27 1974-1985 (2013)
  13. BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure. Duan Q, McMahon S, Anand P, Shah H, Thomas S, Salunga HT, Huang Y, Zhang R, Sahadevan A, Lemieux ME, Brown JD, Srivastava D, Bradner JE, McKinsey TA, Haldar SM. Sci Transl Med 9 eaah5084 (2017)
  14. BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy. Segura MF, Fontanals-Cirera B, Gaziel-Sovran A, Guijarro MV, Hanniford D, Zhang G, González-Gomez P, Morante M, Jubierre L, Zhang W, Darvishian F, Ohlmeyer M, Osman I, Zhou MM, Hernando E. Cancer Res 73 6264-6276 (2013)
  15. BET protein Brd4 activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice. Korb E, Herre M, Zucker-Scharff I, Darnell RB, Allis CD. Nat Neurosci 18 1464-1473 (2015)
  16. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. Zhou B, Hu J, Xu F, Chen Z, Bai L, Fernandez-Salas E, Lin M, Liu L, Yang CY, Zhao Y, McEachern D, Przybranowski S, Wen B, Sun D, Wang S. J Med Chem 61 462-481 (2018)
  17. CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. Hammitzsch A, Tallant C, Fedorov O, O'Mahony A, Brennan PE, Hay DA, Martinez FO, Al-Mossawi MH, de Wit J, Vecellio M, Wells C, Wordsworth P, Müller S, Knapp S, Bowness P. Proc Natl Acad Sci U S A 112 10768-10773 (2015)
  18. NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism. French CA, Rahman S, Walsh EM, Kühnle S, Grayson AR, Lemieux ME, Grunfeld N, Rubin BP, Antonescu CR, Zhang S, Venkatramani R, Dal Cin P, Howley PM. Cancer Discov 4 928-941 (2014)
  19. Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles. Lam FC, Morton SW, Wyckoff J, Vu Han TL, Hwang MK, Maffa A, Balkanska-Sinclair E, Yaffe MB, Floyd SR, Hammond PT. Nat Commun 9 1991 (2018)
  20. Inducible in vivo silencing of Brd4 identifies potential toxicities of sustained BET protein inhibition. Bolden JE, Tasdemir N, Dow LE, van Es JH, Wilkinson JE, Zhao Z, Clevers H, Lowe SW. Cell Rep 8 1919-1929 (2014)
  21. Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors. Ember SW, Zhu JY, Olesen SH, Martin MP, Becker A, Berndt N, Georg GI, Schönbrunn E. ACS Chem Biol 9 1160-1171 (2014)
  22. Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer. Shah N, Wang P, Wongvipat J, Karthaus WR, Abida W, Armenia J, Rockowitz S, Drier Y, Bernstein BE, Long HW, Freedman ML, Arora VK, Zheng D, Sawyers CL. Elife 6 e27861 (2017)
  23. Systematic identification of genes with a cancer-testis expression pattern in 19 cancer types. Wang C, Gu Y, Zhang K, Xie K, Zhu M, Dai N, Jiang Y, Guo X, Liu M, Dai J, Wu L, Jin G, Ma H, Jiang T, Yin R, Xia Y, Liu L, Wang S, Shen B, Huo R, Wang Q, Xu L, Yang L, Huang X, Shen H, Sha J, Hu Z. Nat Commun 7 10499 (2016)
  24. OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models. Berenguer-Daizé C, Astorgues-Xerri L, Odore E, Cayol M, Cvitkovic E, Noel K, Bekradda M, MacKenzie S, Rezai K, Lokiec F, Riveiro ME, Ouafik L. Int J Cancer 139 2047-2055 (2016)
  25. The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models. Garcia PL, Miller AL, Kreitzburg KM, Council LN, Gamblin TL, Christein JD, Heslin MJ, Arnoletti JP, Richardson JH, Chen D, Hanna CA, Cramer SL, Yang ES, Qi J, Bradner JE, Yoon KJ. Oncogene 35 833-845 (2016)
  26. BET Inhibitor JQ1 Blocks Inflammation and Bone Destruction. Meng S, Zhang L, Tang Y, Tu Q, Zheng L, Yu L, Murray D, Cheng J, Kim SH, Zhou X, Chen J. J Dent Res 93 657-662 (2014)
  27. Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression. Qin C, Hu Y, Zhou B, Fernandez-Salas E, Yang CY, Liu L, McEachern D, Przybranowski S, Wang M, Stuckey J, Meagher J, Bai L, Chen Z, Lin M, Yang J, Ziazadeh DN, Xu F, Hu J, Xiang W, Huang L, Li S, Wen B, Sun D, Wang S. J Med Chem 61 6685-6704 (2018)
  28. Differential diagnosis of azoospermia with proteomic biomarkers ECM1 and TEX101 quantified in seminal plasma. Drabovich AP, Dimitromanolakis A, Saraon P, Soosaipillai A, Batruch I, Mullen B, Jarvi K, Diamandis EP. Sci Transl Med 5 212ra160 (2013)
  29. Design and characterization of bivalent BET inhibitors. Tanaka M, Roberts JM, Seo HS, Souza A, Paulk J, Scott TG, DeAngelo SL, Dhe-Paganon S, Bradner JE. Nat Chem Biol 12 1089-1096 (2016)
  30. BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen. Sahai V, Kumar K, Knab LM, Chow CR, Raza SS, Bentrem DJ, Ebine K, Munshi HG. Mol Cancer Ther 13 1907-1917 (2014)
  31. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay. Abruzzese MP, Bilotta MT, Fionda C, Zingoni A, Soriani A, Vulpis E, Borrelli C, Zitti B, Petrucci MT, Ricciardi MR, Molfetta R, Paolini R, Santoni A, Cippitelli M. J Hematol Oncol 9 134 (2016)
  32. Epigenetic targeting of bromodomain protein BRD4 counteracts cancer cachexia and prolongs survival. Segatto M, Fittipaldi R, Pin F, Sartori R, Dae Ko K, Zare H, Fenizia C, Zanchettin G, Pierobon ES, Hatakeyama S, Sperti C, Merigliano S, Sandri M, Filippakopoulos P, Costelli P, Sartorelli V, Caretti G. Nat Commun 8 1707 (2017)
  33. Regulation of NO synthesis, local inflammation, and innate immunity to pathogens by BET family proteins. Wienerroither S, Rauch I, Rosebrock F, Jamieson AM, Bradner J, Muhar M, Zuber J, Müller M, Decker T. Mol Cell Biol 34 415-427 (2014)
  34. The methyltransferase SMYD3 mediates the recruitment of transcriptional cofactors at the myostatin and c-Met genes and regulates skeletal muscle atrophy. Proserpio V, Fittipaldi R, Ryall JG, Sartorelli V, Caretti G. Genes Dev 27 1299-1312 (2013)
  35. Genome-wide chromatin analysis in mature mouse and human spermatozoa. Hisano M, Erkek S, Dessus-Babus S, Ramos L, Stadler MB, Peters AH. Nat Protoc 8 2449-2470 (2013)
  36. Fluorinated aromatic amino acids are sensitive 19F NMR probes for bromodomain-ligand interactions. Mishra NK, Urick AK, Ember SW, Schönbrunn E, Pomerantz WC. ACS Chem Biol 9 2755-2760 (2014)
  37. The bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours in vitro and in vivo. Jostes S, Nettersheim D, Fellermeyer M, Schneider S, Hafezi F, Honecker F, Schumacher V, Geyer M, Kristiansen G, Schorle H. J Cell Mol Med 21 1300-1314 (2017)
  38. Biased multicomponent reactions to develop novel bromodomain inhibitors. McKeown MR, Shaw DL, Fu H, Liu S, Xu X, Marineau JJ, Huang Y, Zhang X, Buckley DL, Kadam A, Zhang Z, Blacklow SC, Qi J, Zhang W, Bradner JE. J Med Chem 57 9019-9027 (2014)
  39. Whole-exome sequencing identified a homozygous BRDT mutation in a patient with acephalic spermatozoa. Li L, Sha Y, Sha Y, Wang X, Li P, Wang J, Kee K, Wang B. Oncotarget 8 19914-19922 (2017)
  40. Epigenetic Readers of Lysine Acetylation Regulate Cocaine-Induced Plasticity. Sartor GC, Powell SK, Brothers SP, Wahlestedt C. J Neurosci 35 15062-15072 (2015)
  41. Nanog requires BRD4 to maintain murine embryonic stem cell pluripotency and is suppressed by bromodomain inhibitor JQ1 together with Lefty1. Horne GA, Stewart HJ, Dickson J, Knapp S, Ramsahoye B, Chevassut T. Stem Cells Dev 24 879-891 (2015)
  42. Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors. Ran X, Zhao Y, Liu L, Bai L, Yang CY, Zhou B, Meagher JL, Chinnaswamy K, Stuckey JA, Wang S. J Med Chem 58 4927-4939 (2015)
  43. Bromodomain and extra-terminal domain bromodomain inhibition prevents synovial inflammation via blocking IκB kinase-dependent NF-κB activation in rheumatoid fibroblast-like synoviocytes. Xiao Y, Liang L, Huang M, Qiu Q, Zeng S, Shi M, Zou Y, Ye Y, Yang X, Xu H. Rheumatology (Oxford) 55 173-184 (2016)
  44. Dysregulation of BRD4 Function Underlies the Functional Abnormalities of MeCP2 Mutant Neurons. Xiang Y, Tanaka Y, Patterson B, Hwang SM, Hysolli E, Cakir B, Kim KY, Wang W, Kang YJ, Clement EM, Zhong M, Lee SH, Cho YS, Patra P, Sullivan GJ, Weissman SM, Park IH. Mol Cell 79 84-98.e9 (2020)
  45. BET protein inhibition mitigates acute myocardial infarction damage in rats via the TLR4/TRAF6/NF-κB pathway. Sun Y, Huang J, Song K. Exp Ther Med 10 2319-2324 (2015)
  46. Knockout of BRD7 results in impaired spermatogenesis and male infertility. Wang H, Zhao R, Guo C, Jiang S, Yang J, Xu Y, Liu Y, Fan L, Xiong W, Ma J, Peng S, Zeng Z, Zhou Y, Li X, Li Z, Li X, Schmitt DC, Tan M, Li G, Zhou M. Sci Rep 6 21776 (2016)
  47. The BET/BRD inhibitor JQ1 improves brain plasticity in WT and APP mice. Benito E, Ramachandran B, Schroeder H, Schmidt G, Urbanke H, Burkhardt S, Capece V, Dean C, Fischer A. Transl Psychiatry 7 e1239 (2017)
  48. Bromodomain and extraterminal (BET) protein inhibition suppresses human T cell leukemia virus 1 (HTLV-1) Tax protein-mediated tumorigenesis by inhibiting nuclear factor κB (NF-κB) signaling. Wu X, Qi J, Bradner JE, Xiao G, Chen LF. J Biol Chem 288 36094-36105 (2013)
  49. Inhibition of BET proteins and epigenetic signaling as a potential treatment for osteoporosis. Baud'huin M, Lamoureux F, Jacques C, Rodriguez Calleja L, Quillard T, Charrier C, Amiaud J, Berreur M, Brounais-LeRoyer B, Owen R, Reilly GC, Bradner JE, Heymann D, Ory B. Bone 94 10-21 (2017)
  50. BRDT is an essential epigenetic regulator for proper chromatin organization, silencing of sex chromosomes and crossover formation in male meiosis. Manterola M, Brown TM, Oh MY, Garyn C, Gonzalez BJ, Wolgemuth DJ. PLoS Genet 14 e1007209 (2018)
  51. Male contraception via simultaneous knockout of α1A-adrenoceptors and P2X1-purinoceptors in mice. White CW, Choong YT, Short JL, Exintaris B, Malone DT, Allen AM, Evans RJ, Ventura S. Proc Natl Acad Sci U S A 110 20825-20830 (2013)
  52. Sodium-hydrogen exchanger NHA1 and NHA2 control sperm motility and male fertility. Chen SR, Chen M, Deng SL, Hao XX, Wang XX, Liu YX. Cell Death Dis 7 e2152 (2016)
  53. Spermatid head elongation with normal nuclear shaping requires ADP-ribosyltransferase PARP11 (ARTD11) in mice. Meyer-Ficca ML, Ihara M, Bader JJ, Leu NA, Beneke S, Meyer RG. Biol Reprod 92 80 (2015)
  54. Characterization of BRD4 during mammalian postmeiotic sperm development. Bryant JM, Donahue G, Wang X, Meyer-Ficca M, Luense LJ, Weller AH, Bartolomei MS, Blobel GA, Meyer RG, Garcia BA, Berger SL. Mol Cell Biol 35 1433-1448 (2015)
  55. Direct and indirect targeting of MYC to treat acute myeloid leukemia. Brondfield S, Umesh S, Corella A, Zuber J, Rappaport AR, Gaillard C, Lowe SW, Goga A, Kogan SC. Cancer Chemother Pharmacol 76 35-46 (2015)
  56. The BET protein FSH functionally interacts with ASH1 to orchestrate global gene activity in Drosophila. Kockmann T, Gerstung M, Schlumpf T, Xhinzhou Z, Hess D, Beerenwinkel N, Beisel C, Paro R. Genome Biol 14 R18 (2013)
  57. Association of DNA methylation and mitochondrial DNA copy number with human semen quality. Tian M, Bao H, Martin FL, Zhang J, Liu L, Huang Q, Shen H. Biol Reprod 91 101 (2014)
  58. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma. Loganathan SN, Tang N, Fleming JT, Ma Y, Guo Y, Borinstein SC, Chiang C, Wang J. Oncotarget 7 43504-43517 (2016)
  59. Bromodomain inhibitors regulate the C9ORF72 locus in ALS. Zeier Z, Esanov R, Belle KC, Volmar CH, Johnstone AL, Halley P, DeRosa BA, Khoury N, van Blitterswijk M, Rademakers R, Albert J, Brothers SP, Wuu J, Dykxhoorn DM, Benatar M, Wahlestedt C. Exp Neurol 271 241-250 (2015)
  60. BET bromodomain inhibition promotes neurogenesis while inhibiting gliogenesis in neural progenitor cells. Li J, Ma J, Meng G, Lin H, Wu S, Wang J, Luo J, Xu X, Tough D, Lindon M, Rioja I, Zhao J, Mei H, Prinjha R, Zhong Z. Stem Cell Res 17 212-221 (2016)
  61. Discovery of methyl 4'-methyl-5-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1'-biphenyl]-3-carboxylate, an improved small-molecule inhibitor of c-Myc-max dimerization. Chauhan J, Wang H, Yap JL, Sabato PE, Hu A, Prochownik EV, Fletcher S. ChemMedChem 9 2274-2285 (2014)
  62. Super-enhancer switching drives a burst in gene expression at the mitosis-to-meiosis transition. Maezawa S, Sakashita A, Yukawa M, Chen X, Takahashi K, Alavattam KG, Nakata I, Weirauch MT, Barski A, Namekawa SH. Nat Struct Mol Biol 27 978-988 (2020)
  63. ZP2 peptide beads select human sperm in vitro, decoy mouse sperm in vivo, and provide reversible contraception. Avella MA, Baibakov BA, Jimenez-Movilla M, Sadusky AB, Dean J. Sci Transl Med 8 336ra60 (2016)
  64. Nonselective inhibition of the epigenetic transcriptional regulator BET induces marked lymphoid and hematopoietic toxicity in mice. Lee DU, Katavolos P, Palanisamy G, Katewa A, Sioson C, Corpuz J, Pang J, DeMent K, Choo E, Ghilardi N, Diaz D, Danilenko DM. Toxicol Appl Pharmacol 300 47-54 (2016)
  65. Structural insights into recognition of acetylated histone ligands by the BRPF1 bromodomain. Lubula MY, Eckenroth BE, Carlson S, Poplawski A, Chruszcz M, Glass KC. FEBS Lett 588 3844-3854 (2014)
  66. BacPROTACs mediate targeted protein degradation in bacteria. Morreale FE, Kleine S, Leodolter J, Junker S, Hoi DM, Ovchinnikov S, Okun A, Kley J, Kurzbauer R, Junk L, Guha S, Podlesainski D, Kazmaier U, Boehmelt G, Weinstabl H, Rumpel K, Schmiedel VM, Hartl M, Haselbach D, Meinhart A, Kaiser M, Clausen T. Cell 185 2338-2353.e18 (2022)
  67. Mouse BAZ1A (ACF1) is dispensable for double-strand break repair but is essential for averting improper gene expression during spermatogenesis. Dowdle JA, Mehta M, Kass EM, Vuong BQ, Inagaki A, Egli D, Jasin M, Keeney S. PLoS Genet 9 e1003945 (2013)
  68. Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma. Zhang X, Zegar T, Lucas A, Morrison-Smith C, Knox T, French CA, Knapp S, Müller S, Siveke JT. Oncogene 39 4770-4779 (2020)
  69. Bioinformatics analysis of thousands of TCGA tumors to determine the involvement of epigenetic regulators in human cancer. Gnad F, Doll S, Manning G, Arnott D, Zhang Z. BMC Genomics 16 Suppl 8 S5 (2015)
  70. Metabolism of JQ1, an inhibitor of bromodomain and extra terminal bromodomain proteins, in human and mouse liver microsomes†. Li F, MacKenzie KR, Jain P, Santini C, Young DW, Matzuk MM. Biol Reprod 103 427-436 (2020)
  71. Site-specific azide-acetyllysine photochemistry on epigenetic readers for interactome profiling. Sudhamalla B, Dey D, Breski M, Nguyen T, Islam K. Chem Sci 8 4250-4256 (2017)
  72. Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen. Schaffer M, Chaturvedi S, Davis C, Aquino R, Stepanchick E, Versele M, Liu Y, Yang J, Lu R, Balasubramanian S. Leuk Lymphoma 59 931-940 (2018)
  73. Human X-linked Intellectual Disability Factor CUL4B Is Required for Post-meiotic Sperm Development and Male Fertility. Lin CY, Chen CY, Yu CH, Yu IS, Lin SR, Wu JT, Lin YH, Kuo PL, Wu JC, Lin SW. Sci Rep 6 20227 (2016)
  74. Photoreceptor protection via blockade of BET epigenetic readers in a murine model of inherited retinal degeneration. Zhao L, Li J, Fu Y, Zhang M, Wang B, Ouellette J, Shahi PK, Pattnaik BR, Watters JJ, Wong WT, Guo LW. J Neuroinflammation 14 14 (2017)
  75. A critical role for c-Myc in group 2 innate lymphoid cell activation. Ye L, Pan J, Liang M, Pasha MA, Shen X, D'Souza SS, Fung ITH, Wang Y, Patel G, Tang DD, Yang Q. Allergy 75 841-852 (2020)
  76. Bromodomain 4 protein is a predictor of survival for urothelial carcinoma of bladder. Yan Y, Yang FQ, Zhang HM, Li J, Li W, Wang GC, Che JP, Zheng JH, Liu M. Int J Clin Exp Pathol 7 4231-4238 (2014)
  77. CRISPR/Cas9-based genome editing in mice uncovers 13 testis- or epididymis-enriched genes individually dispensable for male reproduction†. Sun J, Lu Y, Nozawa K, Xu Z, Morohoshi A, Castaneda JM, Noda T, Miyata H, Abbasi F, Shawki HH, Takahashi S, Devlin DJ, Yu Z, Matzuk RM, Garcia TX, Matzuk MM, Ikawa M. Biol Reprod 103 183-194 (2020)
  78. SLC22A14 is a mitochondrial riboflavin transporter required for sperm oxidative phosphorylation and male fertility. Kuang W, Zhang J, Lan Z, Deepak RNVK, Liu C, Ma Z, Cheng L, Zhao X, Meng X, Wang W, Wang X, Xu L, Jiao Y, Luo Q, Meng Z, Kee K, Liu X, Deng H, Li W, Fan H, Chen L. Cell Rep 35 109025 (2021)
  79. Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor. Zhao Y, Bai L, Liu L, McEachern D, Stuckey JA, Meagher JL, Yang CY, Ran X, Zhou B, Hu Y, Li X, Wen B, Zhao T, Li S, Sun D, Wang S. J Med Chem 60 3887-3901 (2017)
  80. Testicular Busulfan Injection in Mice to Prepare Recipients for Spermatogonial Stem Cell Transplantation Is Safe and Non-Toxic. Qin Y, Liu L, He Y, Wang C, Liang M, Chen X, Hao H, Qin T, Zhao X, Wang D. PLoS One 11 e0148388 (2016)
  81. Bromodomain protein BRDT directs ΔNp63 function and super-enhancer activity in a subset of esophageal squamous cell carcinomas. Wang X, Kutschat AP, Yamada M, Prokakis E, Böttcher P, Tanaka K, Doki Y, Hamdan FH, Johnsen SA. Cell Death Differ 28 2207-2220 (2021)
  82. Bromodomains: pockets with therapeutic potential. Papavassiliou KA, Papavassiliou AG. Trends Mol Med 20 477-478 (2014)
  83. Discovery of a Human Testis-specific Protein Complex TEX101-DPEP3 and Selection of Its Disrupting Antibodies. Schiza C, Korbakis D, Panteleli E, Jarvi K, Drabovich AP, Diamandis EP. Mol Cell Proteomics 17 2480-2495 (2018)
  84. Proteasome subunit α4s is essential for formation of spermatoproteasomes and histone degradation during meiotic DNA repair in spermatocytes. Zhang ZH, Jiang TX, Chen LB, Zhou W, Liu Y, Gao F, Qiu XB. J Biol Chem 296 100130 (2021)
  85. The BET bromodomain inhibitor i-BET151 impairs ovarian cancer metastasis and improves antitumor immunity. Liu A, Fan D, Wang Y. Cell Tissue Res 374 577-585 (2018)
  86. Identification of the Prognostic Signatures of Glioma With Different PTEN Status. Zhang P, Meng X, Liu L, Li S, Li Y, Ali S, Li S, Xiong J, Liu X, Li S, Xia Q, Dong L. Front Oncol 11 633357 (2021)
  87. A Bead-Based Proximity Assay for BRD4 Ligand Discovery. Roberts JM, Bradner JE. Curr Protoc Chem Biol 7 263-278 (2015)
  88. A computational insight into binding modes of inhibitors XD29, XD35, and XD28 to bromodomain-containing protein 4 based on molecular dynamics simulations. Su J, Liu X, Zhang S, Yan F, Zhang Q, Chen J. J Biomol Struct Dyn 36 1212-1224 (2018)
  89. BET inhibitors repress expression of interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma. Gusyatiner O, Bady P, Pham MDT, Lei Y, Park J, Daniel RT, Delorenzi M, Hegi ME. Neuro Oncol 23 1680-1692 (2021)
  90. Development of hedgehog pathway inhibitors by epigenetically targeting GLI through BET bromodomain for the treatment of medulloblastoma. Liu X, Zhang Y, Li Y, Wang J, Ding H, Huang W, Ding C, Liu H, Tan W, Zhang A. Acta Pharm Sin B 11 488-504 (2021)
  91. Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors. Shadrick WR, Slavish PJ, Chai SC, Waddell B, Connelly M, Low JA, Tallant C, Young BM, Bharatham N, Knapp S, Boyd VA, Morfouace M, Roussel MF, Chen T, Lee RE, Kiplin Guy R, Shelat AA, Potter PM. Bioorg Med Chem 26 25-36 (2018)
  92. Low-hanging fruit: targeting Brdt in the testes. Bryant JM, Berger SL. EMBO J 31 3788-3789 (2012)
  93. The Killing of Human Neuroblastoma Cells by the Small Molecule JQ1 Occurs in a p53-Dependent Manner. Mazar J, Gordon C, Naga V, Westmoreland TJ. Anticancer Agents Med Chem 20 1613-1625 (2020)
  94. The polar warhead of a TRIM24 bromodomain inhibitor rearranges a water-mediated interaction network. Liu J, Li F, Bao H, Jiang Y, Zhang S, Ma R, Gao J, Wu J, Ruan K. FEBS J 284 1082-1095 (2017)
  95. BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo. Morse MA, Balogh KK, Brendle SA, Campbell CA, Chen MX, Furze RC, Harada IL, Holyer ID, Kumar U, Lee K, Prinjha RK, Rüdiger M, Seal JT, Taylor S, Witherington J, Christensen ND. Antiviral Res 154 158-165 (2018)
  96. When are the BET factors the most sensitive to bromodomain inhibitors? Khochbin S. Transcription 4 54-57 (2013)
  97. BRDT gene sequence in human testicular pathologies and the implication of its single nucleotide polymorphism (rs3088232) on fertility. Barda S, Yogev L, Paz G, Yavetz H, Lehavi O, Hauser R, Doniger T, Breitbart H, Kleiman SE. Andrology 2 641-647 (2014)
  98. Combined noncanonical NF-κB agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo. Falcinelli SD, Peterson JJ, Turner AW, Irlbeck D, Read J, Raines SL, James KS, Sutton C, Sanchez A, Emery A, Sampey G, Ferris R, Allard B, Ghofrani S, Kirchherr JL, Baker C, Kuruc JD, Gay CL, James LI, Wu G, Zuck P, Rioja I, Furze RC, Prinjha RK, Howell BJ, Swanstrom R, Browne EP, Strahl BD, Dunham RM, Archin NM, Margolis DM. J Clin Invest 132 e157281 (2022)
  99. Contraception for men: a breakthrough new approach. Bremner WJ. Cell 150 667-668 (2012)
  100. N,N Dimethylacetamide a drug excipient that acts as bromodomain ligand for osteoporosis treatment. Ghayor C, Gjoksi B, Dong J, Siegenthaler B, Caflisch A, Weber FE. Sci Rep 7 42108 (2017)
  101. NMR Fragment Screening Hit Induces Plasticity of BRD7/9 Bromodomains. Wang N, Li F, Bao H, Li J, Wu J, Ruan K. Chembiochem 17 1456-1463 (2016)
  102. Report of the First International Symposium on NUT Carcinoma. French CA, Cheng ML, Hanna GJ, DuBois SG, Chau NG, Hann CL, Storck S, Salgia R, Trucco M, Tseng J, Stathis A, Piekarz R, Lauer UM, Massard C, Bennett K, Coker S, Tontsch-Grunt U, Sos ML, Liao S, Wu CJ, Polyak K, Piha-Paul SA, Shapiro GI. Clin Cancer Res 28 2493-2505 (2022)
  103. Toxicity of JQ1 in neuronal derivatives of human umbilical cord mesenchymal stem cells. Bakshi S, McKee C, Walker K, Brown C, Chaudhry GR. Oncotarget 9 33853-33864 (2018)
  104. BRDT promotes ovarian cancer cell growth. Chen L, Cai S, Wang JM, Huai YY, Lu PH, Chu Q. Cell Death Dis 11 1021 (2020)
  105. Drug Repurposing of Bromodomain Inhibitors as Potential Novel Therapeutic Leads for Lymphatic Filariasis Guided by Multispecies Transcriptomics. Chung M, Teigen LE, Libro S, Bromley RE, Olley D, Kumar N, Sadzewicz L, Tallon LJ, Mahurkar A, Foster JM, Michalski ML, Dunning Hotopp JC. mSystems 4 e00596-19 (2019)
  106. Research Support, Non-U.S. Gov't Targeting the BET family for the treatment of leukemia. Lucas X, Günther S. Epigenomics 6 153-155 (2014)
  107. Testicular abnormalities in mice with Y chromosome deficiencies. Ruthig VA, Nielsen T, Riel JM, Yamauchi Y, Ortega EA, Salvador Q, Ward MA. Biol Reprod 96 694-706 (2017)
  108. The bromodomain inhibitor N-methyl pyrrolidone reduced fat accumulation in an ovariectomized rat model. Gjoksi B, Ghayor C, Bhattacharya I, Zenobi-Wong M, Weber FE. Clin Epigenetics 8 42 (2016)
  109. Transient receptor potential-canonical 3 modulates sperm motility and capacitation-associated protein tyrosine phosphorylation via [Ca2+]i mobilization. Ru Y, Zhou Y, Zhang Y. Acta Biochim Biophys Sin (Shanghai) 47 404-413 (2015)
  110. β-Endorphin Induction by Psychological Stress Promotes Leydig Cell Apoptosis through p38 MAPK Pathway in Male Rats. Xiong X, Zhang L, Fan M, Han L, Wu Q, Liu S, Miao J, Liu L, Wang X, Guo B, Tong D, Ni L, Yang J, Huang C. Cells 8 E1265 (2019)
  111. Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections. Modukuri RK, Yu Z, Tan Z, Ta HM, Ucisik MN, Jin Z, Anglin JL, Sharma KL, Nyshadham P, Li F, Riehle K, Faver JC, Duong K, Nagarajan S, Simmons N, Palmer SS, Teng M, Young DW, Yi JS, Kim C, Matzuk MM. Proc Natl Acad Sci U S A 119 e2122506119 (2022)
  112. Effects of epigenetic pathway inhibitors on corticotroph tumour AtT20 cells. Lines KE, Filippakopoulos P, Stevenson M, Müller S, Lockstone HE, Wright B, Knapp S, Buck D, Bountra C, Thakker RV. Endocr Relat Cancer 27 163-174 (2020)
  113. In silico design and bioevaluation of selective benzotriazepine BRD4 inhibitors with potent antiosteoclastogenic activity. Deepak V, Wang B, Koot D, Kasonga A, Stander XX, Coetzee M, Stander A. Chem Biol Drug Des 90 97-111 (2017)
  114. Protein acetylation and spermatogenesis. Pang A, Rennert O. Reprod Syst Sex Disord Suppl 1 5 (2013)
  115. Scalable syntheses of the BET bromodomain inhibitor JQ1. Syeda SS, Jakkaraj S, Georg GI. Tetrahedron Lett 56 3354-3457 (2015)
  116. Two bromodomain proteins functionally interact to recapitulate an essential BRDT-like function in Drosophila spermatocytes. Kimura S, Loppin B. Open Biol 5 140145 (2015)
  117. BET bromodomain inhibitors PFI-1 and JQ1 are identified in an epigenetic compound screen to enhance C9ORF72 gene expression and shown to ameliorate C9ORF72-associated pathological and behavioral abnormalities in a C9ALS/FTD model. Quezada E, Cappelli C, Diaz I, Jury N, Wightman N, Brown RH, Montecino M, van Zundert B. Clin Epigenetics 13 56 (2021)
  118. Development and validation of an LC-MS/MS method to quantify the bromodomain and extra-terminal (BET) inhibitor JQ1 in mouse plasma and brain microdialysate: Application to cerebral microdialysis study. Nair S, Davis A, Campagne O, Schuetz JD, Stewart CF. J Pharm Biomed Anal 204 114274 (2021)
  119. JQ1 is a potential therapeutic option for COPD patients with agrin overexpression. Xiao Z, Shu J, Zhou F, Han Y. Am J Physiol Lung Cell Mol Physiol 314 L690-L694 (2018)
  120. On-demand male contraception via acute inhibition of soluble adenylyl cyclase. Balbach M, Rossetti T, Ferreira J, Ghanem L, Ritagliati C, Myers RW, Huggins DJ, Steegborn C, Miranda IC, Meinke PT, Buck J, Levin LR. Nat Commun 14 637 (2023)
  121. Synthesis of 2-phenyl-5,6,7,8-tetrahydroquinoxaline derivatives and screening for P2X1-purinoceptor antagonist activity in isolated preparations of rat vas deferens, for translation into a male contraceptive†. Mathiew M, Dennis BM, Bennetts F, Su NNE, Nguyen N, Botteon A, Baell JB, Ventura S. Biol Reprod 103 323-332 (2020)
  122. A cell-based high-content screen identifies isocotoin as a small molecule inhibitor of the meiosis-specific MEIOB-SPATA22 complex†. Xu Y, Liu R, Leu NA, Zhang L, Ibragmova I, Schultz DC, Wang PJ. Biol Reprod 103 333-342 (2020)
  123. A-MYB and BRDT-dependent RNA Polymerase II pause release orchestrates transcriptional regulation in mammalian meiosis. Alexander AK, Rice EJ, Lujic J, Simon LE, Tanis S, Barshad G, Zhu L, Lama J, Cohen PE, Danko CG. Nat Commun 14 1753 (2023)
  124. Male fertility: Is spermiogenesis the critical step for answering biomedical issues? Baptissart M, Vega A, Martinot E, Volle DH. Spermatogenesis 3 e24114 (2013)
  125. Parsing the potential of a new male contraceptive. Wolgemuth DJ, Griswold MD, Grimes DA. Nat Med 18 1466-1467 (2012)
  126. Podophyllotoxin Extracted from Juniperus sabina Fruit Inhibits Rat Sperm Maturation and Fertility by Promoting Epididymal Epithelial Cell Apoptosis. Xie S, Li G, Qu L, Zhong R, Chen P, Lu Z, Zhou J, Guo X, Li Z, Ma A, Qian Y, Zhu Y. Evid Based Complement Alternat Med 2017 6958982 (2017)
  127. AAV-mediated gene therapy produces fertile offspring in the Lhcgr-deficient mouse model of Leydig cell failure. Xia K, Wang F, Lai X, Dong L, Luo P, Zhang S, Yang C, Chen H, Ma Y, Huang W, Ou W, Li Y, Feng X, Yang B, Liu C, Lei Z, Tu X, Ke Q, Mao FF, Deng C, Xiang AP. Cell Rep Med 3 100792 (2022)
  128. BET Proteins Regulate Expression of Osr1 in Early Kidney Development. Schreiber J, Liaukouskaya N, Fuhrmann L, Hauser AT, Jung M, Huber TB, Wanner N. Biomedicines 9 1878 (2021)
  129. BET bromodomain inhibitor JQ1 regulates spermatid development by changing chromatin conformation in mouse spermatogenesis. Wang X, Sang M, Gong S, Chen Z, Zhao X, Wang G, Li Z, Huang Y, Chen S, Xie G, Duan E, Sun F. Genes Dis 9 1062-1073 (2022)
  130. BET protein inhibition in macrophages enhances dorsal root ganglion neurite outgrowth in female mice. Palomés-Borrajo G, Navarro X, Penas C. J Neurosci Res 100 1331-1346 (2022)
  131. Comment BETting on a new prostate cancer treatment. Asangani IA, Chinnaiyan AM. Cell Cycle 13 2015-2016 (2014)
  132. Binding specificity and function of the SWI/SNF subunit SMARCA4 bromodomain interaction with acetylated histone H3K14. Enríquez P, Krajewski K, Strahl BD, Rothbart SB, Dowen RH, Rose RB. J Biol Chem 297 101145 (2021)
  133. Blocking the Bromodomains Function Contributes to Disturbances in Alga Chara vulgaris Spermatids Differentiation. Wojtczak A. Cells 9 E1352 (2020)
  134. Genomic Identification, Evolution, and Expression Analysis of Bromodomain Genes Family in Buffalo. Zhang J, Huang L, Zhang P, Huang X, Yang W, Liu R, Sun Q, Lu Y, Zhang M, Fu Q. Genes (Basel) 13 103 (2022)
  135. Editorial It is time for new male contraceptives! Wang C, Sitruk-Ware R, Serfaty D. Andrology 4 773-775 (2016)
  136. JQ-1 ameliorates schistosomiasis liver granuloma in mice by suppressing male and female reproductive systems and egg development of Schistosoma japonicum. Tian J, Dai B, Gong L, Wang P, Ding H, Xia S, Sun W, Ren C, Shen J, Liu M. PLoS Negl Trop Dis 16 e0010661 (2022)
  137. Reversible Contraceptive Potential of FDA Approved Excipient N, N-Dimethylacetamide in Male Rats. Khera N, Ghayor C, Lindholm AK, Pavlova E, Atanassova N, Weber FE. Front Physiol 11 601084 (2020)
  138. Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study. Moreno V, Manuel Sepúlveda J, Reardon DA, Pérez-Núñez Á, González León P, Hanna B, Filvaroff E, Aronchik I, Chang H, Amoroso B, Zuraek M, Sanchez-Perez T, Mendez C, Stephens D, Nikolova Z, Vogelbaum MA. Neuro Oncol 25 1113-1122 (2023)
  139. 1,4-Dihydropyridinebutyrolactone-derived ring-opened ester and amide analogs targeting BET bromodomains. Jiang J, Zhao PL, Sigua LH, Chan A, Schönbrunn E, Qi J, Georg GI. Arch Pharm (Weinheim) 355 e2200288 (2022)
  140. Backbone and side-chain NMR assignments for the bromodomain of mouse BAZ1A (ACF1). Fan K, Chen S, Ge Y, Ye K, Yao Q, Jing J, Zhang J, Tu X, Yao B. Biomol NMR Assign 10 131-134 (2016)
  141. Basic research: Mouse study shows spermatogenesis inhibitor is effective as a reversible male contraceptive. Fenner A. Nat Rev Urol 9 544 (2012)
  142. Chemical Catalysis Guides Structural Identification for the Major In Vivo Metabolite of the BET Inhibitor JQ1. Holmes S, Jain P, Rodriguez KG, Williams J, Yu Z, Cerda-Smith C, Samuel ELG, Campbell J, Hakenjos JM, Monsivais D, Li F, Chamakuri S, Matzuk MM, Santini C, MacKenzie KR, Young DW. ACS Med Chem Lett 15 107-115 (2024)
  143. Congress Conference scene: 2nd cancer epigenetics conference. Smith CL. Epigenomics 5 123-130 (2013)
  144. Defining super-enhancers by highly ranked histone H4 multi-acetylation levels identifies transcription factors associated with glioblastoma stem-like properties. Das ND, Chang JC, Hon CC, Kelly ST, Ito S, Lizio M, Kaczkowski B, Watanabe H, Katsushima K, Natsume A, Koseki H, Kondo Y, Minoda A, Umehara T. BMC Genomics 24 574 (2023)
  145. Evaluation of a Zinc Gluconate Neutralized with Arginine Product as a Nonsurgical Method for Sterilization of Rhesus Macaques (Macaca mulatta). Woodward KN, Keesler RI, Reader JR, Christe KL. J Am Assoc Lab Anim Sci 56 520-526 (2017)
  146. Genome-Wide Identification and Characterization of the BRD Family in Nile Tilapia (Oreochromis niloticus). Xu C, Yu M, Zhang Q, Ma Z, Du K, You H, Wei J, Wang D, Tao W. Animals (Basel) 12 2266 (2022)
  147. Inflammatory disorders: Separating good from bad. Harrison C. Nat Rev Drug Discov 11 750 (2012)
  148. Overcoming therapeutic resistance in oncolytic herpes virotherapy by targeting IGF2BP3-induced NETosis in malignant glioma. Dai W, Tian R, Yu L, Bian S, Chen Y, Yin B, Luan Y, Chen S, Fan Z, Yan R, Pan X, Hou Y, Li R, Chen J, Shu M. Nat Commun 15 131 (2024)
  149. Profile of Martin Matzuk. Viegas J. Proc Natl Acad Sci U S A 113 7688-7689 (2016)
  150. Small Molecule Ligands of the BET-like Bromodomain, SmBRD3, Affect Schistosoma mansoni Survival, Oviposition, and Development. Schiedel M, McArdle DJB, Padalino G, Chan AKN, Forde-Thomas J, McDonough M, Whiteland H, Beckmann M, Cookson R, Hoffmann KF, Conway SJ. J Med Chem 66 15801-15822 (2023)
  151. The novel BRDT inhibitor NHWD870 shows potential as a male contraceptive in mice. Wu S, Li X, Shang L, Wu L, Li T, Li P, Ji Z, Hou J, Yin M, Xu W. Acta Biochim Biophys Sin (Shanghai) 54 1789-1800 (2022)
  152. [Coming soon: the pill for men?]. Zündorf I, Dingermann T. Pharm Unserer Zeit 41 442-443 (2012)
  153. [Therapeutic issues concerning male fertility]. Bernard V, Bouvattier C, Christin-Maitre S. Ann Endocrinol (Paris) 75 Suppl 1 S13-20 (2014)


Quick links